Overview
The Starr Technology Commercialization Fund (Starr TCF) is an initiative by the Starr Cancer Consortium (SCC) funded by the Starr Foundation. The purpose of the Starr TCF is to provide the requisite support to collaborative projects previously funded by the SCC so that Intellectual Property (IP) from that project can reach a commercialization endpoint.
The Starr TCF Request for Proposal (RFP) solicits two types of proposals from SCC-funded projects for:
Early drug discovery research. Pre-existing IP is not required. Funding is awarded in anticipation that IP will be generated and protected.
Commercial development of IP from the SCC-funded project
Eligibility Criteria
Funding is available to projects previously-funded by the Starr Cancer Consortium, i.e. awards from the 1st through 12th SCC grant competitions, for early drug discovery research and commercial development of IP, as follows:
Early drug discovery research based on compelling preliminary data from the SCC-funded project; pre-existing IP is not required; funding is awarded in anticipation that IP will be generated and protected.
Commercial development of IP generated or improved by the SCC-funded project; such IP is owned by one or more of the SCC member institutions that participated in the previously-funded collaborative project and steps have been taken to protect it; the IP is at a later stage in the development cycle such that rate limiting steps to reach a commercialization endpoint may, but need not include some or all of the following: international patent applications, laboratory and animal studies enabling an Investigational New Drug Application with US Food and Drug Administration; drug manufacturing, including scale-up and formulation and license fees for acquiring enabling technology rights for manufacturing; Phase 1 clinical trial; a business plan; and/or initial financing, if a new company is the appropriate commercialization endpoint.
4th Starr Technology Commercialization Fund competition
In the 4th Starr TCF competition, 3 Letters of Intent were received (2 for early drug discovery research, 1 for commercial development of IP); 2 applications were invited; no awards were made.
3rd Starr Technology Commercialization Fund competition
In the 3rd Starr TCF competition, 3 Letters of Intent were received (2 for early drug discovery research, 1 for commercial development of IP); 3 applications were invited; 1 award was made for early drug discovery research.
2nd Starr Technology Commercialization Fund competition
In the 2nd Starr TCF competition, 2 Letters of Intent were received; 2 applications were invited; no awards were made.
1st Starr Technology Commercialization Fund competition
In the 1st Starr TCF competition, 6 Letters of Intent were received; 4 applications were invited; 1 award was made.
For further information contact:
Sylvie Le Blancq, Ph.D.
Executive Director
Starr Cancer Consortium
Tel: 646 888 3773
Email: leblancs@mskcc.org